Orally available IL17A small molecule antagonists could extend these benefits to a larger number of patients who dislike the needle-based injections needed to administer such anti-IL17 antibodies or need to more quickly wash out IL17 antagonism in the event of fungal or other infections. This evidence concerns the gene IL17A and infection.